We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Read MoreHide Full Article
Key Takeaways
NTLA reported Q4 loss of 83 cents per share and revenues of $23M, beating estimates for both.
NTLA revenues rose 74% Y/Y, driven by Regeneron collaboration reimbursements and other revenues.
Intellia expects lonvo-z top-line data by mid-2026 and targets lonvo-z U.S. launch in H1 2027.
Intellia Therapeutics (NTLA - Free Report) reported a fourth-quarter 2025 loss of 83 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of 99 cents. In the year-ago quarter, the company had incurred a loss of $1.27 per share.
Intellia’s total revenues currently comprise only collaboration revenues. The company reported revenues of $23 million for the fourth quarter of 2025, beating the Zacks Consensus Estimate of $12 million. Total revenues surged 73.8% on a year-over-year basis, driven by cost reimbursements related to NTLA’s collaboration with Regeneron Pharmaceuticals (REGN - Free Report) and $9 million in revenues recognized from the termination of its license and collaboration agreement with SparingVision SAS.
Shares of Intellia were up 6.4% yesterday, owing to the better-than-expected fourth-quarter results. The stock has gained 24% in the past six months compared with the industry’s rise of 22.4%.
Image Source: Zacks Investment Research
NTLA’s Q4 Results in Detail
Research and development expenses totaled $88.7 million, down 24.1% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and other costs, partially offset by increased spending in pipeline studies.
General and administrative expenses in the fourth quarter were $33.1 million, up 2.2% on a year-over-year basis.
As of Dec. 31, 2025, Intellia had cash, cash equivalents and marketable securities worth $605.1 million compared with $669.9 million as of Sept. 30, 2025.
The company expects this cash balance to fund its ongoing operations into the second half of 2027 and the anticipated first commercial launch of its pipeline candidate, lonvo-z, which is being studied for hereditary angioedema (HAE).
NTLA’s Full-Year Results
For 2025, Intellia generated revenues of $67.7 million compared with $57.9 million recorded in the year-ago quarter.
For the same period, the company reported a loss of $3.81 per share, narrower than a loss of $5.25 reported in the year-ago period.
NTLA's Recent Pipeline Updates
Intellia has collaborated with Regeneron for the development of its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Last month, the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III study, MAGNITUDE-2, evaluating nex-z in patients with ATTRv-PN. Enrollment in the study is expected to be completed in the second half of 2026.
In October 2025, Intellia halted dosing and patient enrollment in the MAGNITUDE and MAGNITUDE-2 studies, which evaluated nex-z for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTRv-PN, respectively.
Intellia is currently engaging with FDA officials to resolve the clinical hold on the phase III MAGNITUDE study. Management expects to share an update on the same once it reaches an agreement with the regulatory body on the next steps for the program.
Intellia is developing lonvo-z for the treatment of HAE. The company completed enrolling HAE patients in the pivotal phase III HAELO study evaluating lonvo-z in September 2025 and expects to share top-line data by mid-2026. If data from the study is found to be positive, the company plans to submit a potential biologics license application for lonvo-z in HAE in the second half of 2026. An anticipated launch for lonvo-z in the United States is expected in the first half of 2027.
Intellia Therapeutics, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, Castle Biosciences’ 2026 loss per share estimates have narrowed from $1.06 to 96 cents. CSTL’s shares have rallied 54.6% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Over the past 60 days, Arcus Biosciences’ 2026 loss per share estimates have narrowed from $3.90 to $3.86. RCUS’ shares have soared 88.2% in the past six months.
Arcus Biosciences’ earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 28.14%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Key Takeaways
Intellia Therapeutics (NTLA - Free Report) reported a fourth-quarter 2025 loss of 83 cents per share (including one-time expenses of change in fair value of investments), narrower than the Zacks Consensus Estimate of a loss of 99 cents. In the year-ago quarter, the company had incurred a loss of $1.27 per share.
Intellia’s total revenues currently comprise only collaboration revenues. The company reported revenues of $23 million for the fourth quarter of 2025, beating the Zacks Consensus Estimate of $12 million. Total revenues surged 73.8% on a year-over-year basis, driven by cost reimbursements related to NTLA’s collaboration with Regeneron Pharmaceuticals (REGN - Free Report) and $9 million in revenues recognized from the termination of its license and collaboration agreement with SparingVision SAS.
Shares of Intellia were up 6.4% yesterday, owing to the better-than-expected fourth-quarter results. The stock has gained 24% in the past six months compared with the industry’s rise of 22.4%.
Image Source: Zacks Investment Research
NTLA’s Q4 Results in Detail
Research and development expenses totaled $88.7 million, down 24.1% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and other costs, partially offset by increased spending in pipeline studies.
General and administrative expenses in the fourth quarter were $33.1 million, up 2.2% on a year-over-year basis.
As of Dec. 31, 2025, Intellia had cash, cash equivalents and marketable securities worth $605.1 million compared with $669.9 million as of Sept. 30, 2025.
The company expects this cash balance to fund its ongoing operations into the second half of 2027 and the anticipated first commercial launch of its pipeline candidate, lonvo-z, which is being studied for hereditary angioedema (HAE).
NTLA’s Full-Year Results
For 2025, Intellia generated revenues of $67.7 million compared with $57.9 million recorded in the year-ago quarter.
For the same period, the company reported a loss of $3.81 per share, narrower than a loss of $5.25 reported in the year-ago period.
NTLA's Recent Pipeline Updates
Intellia has collaborated with Regeneron for the development of its investigational in vivo genome-editing candidate, nexiguran ziclumeran (nex-z), which is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Last month, the FDA lifted the clinical hold on the investigational new drug application (IND) for the phase III study, MAGNITUDE-2, evaluating nex-z in patients with ATTRv-PN. Enrollment in the study is expected to be completed in the second half of 2026.
In October 2025, Intellia halted dosing and patient enrollment in the MAGNITUDE and MAGNITUDE-2 studies, which evaluated nex-z for ATTR amyloidosis with cardiomyopathy (ATTR-CM) and ATTRv-PN, respectively.
Intellia is currently engaging with FDA officials to resolve the clinical hold on the phase III MAGNITUDE study. Management expects to share an update on the same once it reaches an agreement with the regulatory body on the next steps for the program.
Intellia is developing lonvo-z for the treatment of HAE. The company completed enrolling HAE patients in the pivotal phase III HAELO study evaluating lonvo-z in September 2025 and expects to share top-line data by mid-2026. If data from the study is found to be positive, the company plans to submit a potential biologics license application for lonvo-z in HAE in the second half of 2026. An anticipated launch for lonvo-z in the United States is expected in the first half of 2027.
Intellia Therapeutics, Inc. Price, Consensus and EPS Surprise
Intellia Therapeutics, Inc. price-consensus-eps-surprise-chart | Intellia Therapeutics, Inc. Quote
NTLA’s Zacks Rank & Stocks to Consider
Intellia currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the biotech sector are Castle Biosciences (CSTL - Free Report) and Arcus Biosciences (RCUS - Free Report) . While Castle Biosciences currently sports a Zacks Rank #1 (Strong Buy), Arcus Biosciences holds a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, Castle Biosciences’ 2026 loss per share estimates have narrowed from $1.06 to 96 cents. CSTL’s shares have rallied 54.6% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Over the past 60 days, Arcus Biosciences’ 2026 loss per share estimates have narrowed from $3.90 to $3.86. RCUS’ shares have soared 88.2% in the past six months.
Arcus Biosciences’ earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 28.14%.